Last updated: February 8, 2026
Case Overview
Shire LLC and Supernus Pharmaceuticals Inc. filed a patent infringement lawsuit against Impax Laboratories Inc. in the District Court for the Northern District of California in 2010. The plaintiffs accused Impax of infringing U.S. Patent Nos. 6,440,828 and 7,187,781, which cover formulations related to neurological disorder treatments.
Key Timeline and Proceedings
- Filing Date: September 30, 2010
- Pleadings: Plaintiffs alleged that Impax's generic versions of Shire and Supernus's respective drugs infringed held patents.
- Claimed Patent Scope: Cover formulations of extended-release formulations for medications treating ADHD and narcolepsy.
- Trial and Rulings: The case involved multiple dispositive motions, including motions for summary judgment and patent validity challenges, leading to significant procedural developments.
- Resolution: The litigation was ultimately settled in 2012 prior to a scheduled trial date.
Patent Claims and Scope
- The '828 patent covers a specific extended-release formulation of methylphenidate.
- The '781 patent claims methods of making controlled-release formulations.
- The patents aimed to protect innovations in drug delivery systems, particularly for sustained-release formulations, which were critical for extending the duration of pharmacological effects and improving patient compliance.
Infringement Allegations
Impax launched a generic methylphenidate product, infringing the asserted patents. Plaintiffs alleged that Impax's formulations incorporated the claimed features, such as specific polymer matrices and controlled-release mechanisms protected by the patents.
Legal Analysis
- Patent Validity: The defendants challenged the validity of the patents citing obviousness and lack of novelty based on prior art references.
- Infringement: Evidence was presented to show that Impax’s generic formulations embodied the patented features.
- Settlement: The case settled before a final judgment, with Impax agreeing to certain licensing or royalty arrangements, typical in Hatch-Waxman patent litigations.
Legal and Market Implications
- The litigation underscores the importance of formulation patents in the generic drug market.
- Validity challenges highlight the necessity for robust patent drafting and prosecution strategies.
- Settlements often result in delayed generic entry, impacting market competition and drug pricing.
Impact on Stakeholders
- Pharmaceutical Innovators: Reinforces reliance on patent protections to secure exclusive sales periods.
- Generic Manufacturers: Demonstrates the risk of infringement claims and validity challenges under patent litigations.
- Regulators and Courts: Maintain the role of balancing patent rights with promoting generic drug entry, often resulting in settlements.
Key Patent and Litigation Trends
- Patent disputes involving formulations are prevalent in the neuropharmacology space due to high patenting activity.
- Settlements in patent litigation for extended-release formulations are common, often involving licensing agreements rather than court rulings.
- Patent challenges tend to focus on obviousness and prior art references, emphasizing the need for precise claims and comprehensive prosecution.
Key Takeaways
- The case exemplifies the strategic importance of formulation patents in the pharmaceutical industry.
- Litigation was settled before trial, underscoring the frequent settlement pattern in Hatch-Waxman disputes.
- Patent validity remains a contested issue, especially around obviousness and prior art.
- Formulation patents can significantly delay generic entry, affecting market dynamics.
- Stakeholders should focus on comprehensive patent drafting and proactive enforcement.
FAQs
1. What was the main patent at stake in this case?
The litigation focused on U.S. Patent Nos. 6,440,828 and 7,187,781, covering controlled-release methylphenidate formulations.
2. Why did Impax face patent infringement claims?
Impax’s generic methylphenidate drug allegedly incorporated formulation features protected by the plaintiffs’ patents.
3. What legal defenses did Impax raise?
Impax challenged the patents' validity, particularly arguing that they were obvious based on prior art references.
4. How was the case resolved?
The parties settled in 2012, avoiding a court judgment, typically involving licensing agreements.
5. What do these proceedings imply for pharmaceutical patent strategies?
Robust patent claims, thorough prosecution, and early enforcement are essential to defend formulations in the face of generic competition.
Citations
[1] U.S. District Court for the Northern District of California, Case No. 3:10-cv-05467.
[2] Patent Nos. 6,440,828; 7,187,781.
[3] Public records of patent litigation history and settlement reports.
